BlackRock Health Sciences Trust Key Executives
This section highlights BlackRock Health Sciences Trust's key executives, including their titles and compensation details.
Find Contacts at BlackRock Health Sciences Trust
(Showing 0 of )
BlackRock Health Sciences Trust Earnings
This section highlights BlackRock Health Sciences Trust's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.
$38.72
Stock Price
$513.25M
Market Cap
-
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for BlackRock Health Sciences Trust, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $24.07M | $20.41M | $-25.97M | $- | $- |
| Cost of Revenue | $- | $-8.46M | $- | $- | $- |
| Gross Profit | $24.07M | $28.87M | $-25.97M | $- | $- |
| Gross Profit Ratio | 100.00% | 141.47% | 100.00% | 0.00% | 0.00% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $355.53K | $299.03K | $362.16K | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $355.53K | $299.03K | $362.16K | $- | $- |
| Other Expenses | $23.72M | $20.11M | $-26.33M | $- | $- |
| Operating Expenses | $24.07M | $20.41M | $-25.97M | $- | $- |
| Cost and Expenses | $24.07M | $20.41M | $-25.97M | $- | $- |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $78 | $55 | $- | $- | $- |
| Depreciation and Amortization | $- | $11.56M | $228.49K | $236.56K | $206.30K |
| EBITDA | $- | $20.02M | $- | $- | $- |
| EBITDA Ratio | 0.00% | 98.11% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-46.91M | $8.46M | $- | $- | $- |
| Operating Income Ratio | -194.87% | 41.47% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $70.36M | $11.55M | $-26.47M | $- | $- |
| Income Before Tax | $23.45M | $20.02M | $-26.47M | $- | $- |
| Income Before Tax Ratio | 97.44% | 98.07% | 101.93% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $- | $- |
| Net Income | $23.45M | $20.02M | $-26.47M | $- | $- |
| Net Income Ratio | 97.44% | 98.07% | 101.93% | 0.00% | 0.00% |
| EPS | $1.68 | $1.44 | $-2.10 | $-2.55 | $11.63 |
| EPS Diluted | $1.68 | $1.44 | $-2.10 | $-2.55 | $11.63 |
| Weighted Average Shares Outstanding | 13.94M | 13.94M | 12.61M | 112.88M | 112.70M |
| Weighted Average Shares Outstanding Diluted | 13.94M | 13.94M | 12.61M | 112.88M | 112.70M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2024 | December 31, 2023 | June 30, 2023 |
|---|---|---|---|
| Revenue | $-383.86K | $18.29M | $16.61M |
| Cost of Revenue | $3.09M | $3.02M | $3.00M |
| Gross Profit | $-3.47M | $15.27M | $13.60M |
| Gross Profit Ratio | 903.99% | 83.50% | 81.90% |
| Research and Development Expenses | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- |
| Selling General and Administrative Expenses | $-49.44M | $6.56M | $2.29M |
| Other Expenses | $- | $- | $- |
| Operating Expenses | $-49.44M | $6.56M | $2.29M |
| Cost and Expenses | $-46.36M | $9.58M | $5.29M |
| Interest Income | $- | $- | $- |
| Interest Expense | $- | $- | $- |
| Depreciation and Amortization | $- | $- | $- |
| EBITDA | $45.97M | $8.71M | $11.31M |
| EBITDA Ratio | -11976.69% | 47.62% | 68.14% |
| Operating Income | $45.97M | $8.71M | $11.31M |
| Operating Income Ratio | -11976.69% | 47.62% | 68.14% |
| Total Other Income Expenses Net | $-26.73K | $-4.02K | $-3.56K |
| Income Before Tax | $45.95M | $8.71M | $11.31M |
| Income Before Tax Ratio | -11969.72% | 47.60% | 68.11% |
| Income Tax Expense | $- | $- | $- |
| Net Income | $45.95M | $8.71M | $11.31M |
| Net Income Ratio | -11969.72% | 47.60% | 68.11% |
| EPS | $3.30 | $0.62 | $0.81 |
| EPS Diluted | $3.30 | $0.62 | $0.81 |
| Weighted Average Shares Outstanding | 13.94M | 13.94M | 13.94M |
| Weighted Average Shares Outstanding Diluted | 13.94M | 13.94M | 13.94M |
| SEC Filing | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $71.34K | $534 | $3.12K | $960 | $33.69K |
| Short Term Investments | $- | $- | $- | $- | $2.51B |
| Cash and Short Term Investments | $71.34K | $534 | $3.12K | $960 | $33.69K |
| Net Receivables | $1.20M | $1.58M | $2.37M | $3.18M | $375.66K |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $-1.20M | $-1.62M | $-2.37M | $-3.18M | $- |
| Total Current Assets | $71.34K | $-37.84K | $3.12K | $960 | $409.35K |
| Property Plant Equipment Net | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $773.33M | $594.40M | $603.68M | $645.54M | $553.11M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-773.33M | $- | $-603.68M | $-645.54M | $-553.11M |
| Total Non-Current Assets | $774.52M | $594.40M | $606.13M | $648.81M | $-2.51B |
| Other Assets | $774.59M | $1.74M | $606.13M | $648.81M | $3.07B |
| Total Assets | $774.59M | $596.10M | $606.13M | $648.81M | $554.55M |
| Account Payables | $- | $- | $233.20K | $12.48M | $114.21K |
| Short Term Debt | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $- | $- | $-233.20K | $-12.48M | $-114.21K |
| Total Current Liabilities | $- | $- | $- | $- | $-1.17M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- |
| Other Liabilities | $6.03M | $7.97M | $5.93M | $23.04M | $8.62M |
| Total Liabilities | $6.03M | $7.97M | $5.93M | $23.04M | $64.01M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $942.10M | $417.62M | $424.30M | $390.51M | $339.11M |
| Retained Earnings | $-173.53M | $170.52M | $175.90M | $235.27M | $206.83M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $- | $- | $- | $- | $2.48B |
| Total Stockholders Equity | $768.57M | $588.14M | $600.20M | $625.77M | $3.02B |
| Total Equity | $768.57M | $588.14M | $600.20M | $625.77M | $3.02B |
| Total Liabilities and Stockholders Equity | $774.59M | $596.10M | $606.13M | $648.81M | $554.55M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $774.59M | $596.10M | $606.13M | $648.81M | $554.55M |
| Total Investments | $773.33M | $594.40M | $603.68M | $645.54M | $3.07B |
| Total Debt | $- | $- | $- | $- | $- |
| Net Debt | $-71.34K | $-534 | $-3.12K | $-960 | $-211.70K |
Balance Sheet Charts
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $71.34K | $1.14K | $534 | $606 | $33.69K | $- | $501.31K | $- |
| Short Term Investments | $- | $19.94M | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $71.34K | $19.94M | $534 | $606 | $33.69K | $- | $501.31K | $- |
| Net Receivables | $1.20M | $3.16M | $1.62M | $3.99M | $375.66K | $1.18M | $574.41K | $1.48M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $-1.20M | $-23.10M | $-1.62M | $-3.99M | $- | $- | $- | $- |
| Total Current Assets | $71.34K | $23.47M | $534 | $606 | $409.35K | $1.18M | $1.08M | $1.48M |
| Property Plant Equipment Net | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $773.33M | $601.80M | $594.40M | $603.71M | $3.07B | $2.06B | $1.72B | $1.58B |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-773.33M | $-601.80M | $-594.40M | $-603.71M | $-3.07B | $-2.06B | $-1.72B | $-1.58B |
| Total Non-Current Assets | $774.52M | $601.80M | $596.10M | $607.78M | $3.07B | $2.06B | $1.72B | $1.58B |
| Other Assets | $774.59M | $625.28M | $596.10M | $607.78M | $19.40M | $9.00M | $8.75M | $- |
| Total Assets | $774.59M | $625.28M | $596.10M | $607.78M | $3.09B | $2.07B | $1.73B | $1.58B |
| Account Payables | $- | $172.78K | $- | $528.07K | $1.76M | $1.56M | $1.52M | $163.40M |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $- | $-172.78K | $- | $-528.07K | $-1.76M | $-1.56M | $-1.52M | $-163.40M |
| Total Current Liabilities | $- | $1.23M | $- | $- | $1.76M | $1.56M | $1.52M | $163.40M |
| Long Term Debt | $- | $1.03M | $- | $- | $- | $127.49K | $- | $7.01M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $-1.03M | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $127.49K | $- | $7.01M |
| Other Liabilities | $6.03M | $9.02M | $7.97M | $10.53M | $64.01M | $50.22M | $93.49M | $2.07M |
| Total Liabilities | $6.03M | $9.02M | $7.97M | $10.53M | $64.01M | $51.91M | $93.49M | $172.49M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $942.10M | $417.62M | $417.62M | $427.83M | $1.51B | $1.52B | $1.52B | $1.40B |
| Retained Earnings | $-173.53M | $- | $170.52M | $169.42M | $1.52B | $500.70M | $117.28M | $6.43M |
| Accumulated Other Comprehensive Income Loss | $- | $198.64M | $- | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $768.57M | $616.26M | $588.14M | $597.25M | $3.02B | $2.02B | $1.64B | $1.41B |
| Total Equity | $768.57M | $616.26M | $588.14M | $597.25M | $3.02B | $2.02B | $1.64B | $1.41B |
| Total Liabilities and Stockholders Equity | $774.59M | $625.28M | $596.10M | $607.78M | $3.09B | $2.07B | $1.73B | $1.58B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $774.59M | $625.28M | $596.10M | $607.78M | $3.09B | $2.07B | $1.73B | $1.58B |
| Total Investments | $773.33M | $621.75M | $594.40M | $603.71M | $3.07B | $2.06B | $1.72B | $1.58B |
| Total Debt | $- | $1.04M | $- | $- | $- | $127.49K | $- | $7.01M |
| Net Debt | $-71.34K | $1.04M | $-534 | $-606 | $-33.69K | $127.49K | $-501.31K | $7.01M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $23.45M | $20.02M | $-26.47M | $59.12M | $79.56M |
| Depreciation and Amortization | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- |
| Change in Working Capital | $509.26K | $-765.40K | $325.08K | $246.20K | $-385.09K |
| Accounts Receivables | $215.91K | $-17.82K | $-146.89K | $5.45K | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $-267.88K |
| Other Working Capital | $293.36K | $-747.58K | $471.97K | $240.75K | $-117.21K |
| Other Non Cash Items | $41.56M | $12.77M | $25.27M | $-80.92M | $-98.53M |
| Net Cash Provided by Operating Activities | $65.52M | $32.02M | $-874.04K | $-21.56M | $-19.35M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-35.55K | $-970.25K |
| Net Cash Used for Investing Activities | $- | $- | $- | $-35.55K | $-970.25K |
| Debt Repayment | $-60.69K | $57.77K | $2.92K | $- | $- |
| Common Stock Issued | $- | $3.02M | $33.62M | $50.33M | $45.09M |
| Common Stock Repurchased | $-29.53M | $- | $- | $- | $- |
| Dividends Paid | $-35.92M | $-35.10M | $-32.73M | $-29.00M | $-25.65M |
| Other Financing Activities | $- | $-497 | $-19.93K | $20.43K | $- |
| Net Cash Used Provided by Financing Activities | $-65.52M | $-32.02M | $876.17K | $21.34M | $19.44M |
| Effect of Forex Changes on Cash | $-7 | $-28 | $32 | $-1 | $- |
| Net Change in Cash | $5.51K | $-2.58K | $2.16K | $-210.74K | $10.18M |
| Cash at End of Period | $6.05K | $534 | $3.12K | $960 | $211.70K |
| Cash at Beginning of Period | $534 | $3.12K | $960 | $211.70K | $125.20K |
| Operating Cash Flow | $65.52M | $32.02M | $-874.04K | $-21.56M | $-19.35M |
| Capital Expenditure | $- | $- | $-1 | $-4 | $- |
| Free Cash Flow | $65.52M | $32.02M | $-874.04K | $-21.56M | $-19.35M |
Cash Flow Charts
| Breakdown | June 30, 2024 | December 31, 2023 | June 30, 2023 |
|---|---|---|---|
| Net Income | $45.95M | $8.71M | $11.31M |
| Depreciation and Amortization | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- |
| Change in Working Capital | $1.17M | $-2.97M | $2.20M |
| Accounts Receivables | $136.44K | $79.75K | $-97.57K |
| Inventory | $- | $- | $- |
| Accounts Payables | $15.61K | $-456.74K | $435.02K |
| Other Working Capital | $1.02M | $-2.59M | $1.86M |
| Other Non Cash Items | $-53.81M | $-7.49M | $-7.00M |
| Net Cash Provided by Operating Activities | $-6.69M | $-1.75M | $6.51M |
| Investments in Property Plant and Equipment | $- | $- | $- |
| Acquisitions Net | $- | $- | $- |
| Purchases of Investments | $-52.83M | $-125.85M | $-115.89M |
| Sales Maturities of Investments | $65.78M | $148.97M | $127.55M |
| Other Investing Activities | $- | $- | $- |
| Net Cash Used for Investing Activities | $12.95M | $23.12M | $11.66M |
| Debt Repayment | $-60.69K | $-35.50K | $93.27K |
| Common Stock Issued | $- | $- | $3.02M |
| Common Stock Repurchased | $- | $- | $- |
| Dividends Paid | $-17.65M | $-17.99M | $-17.11M |
| Other Financing Activities | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-17.71M | $-18.03M | $-14.00M |
| Effect of Forex Changes on Cash | $- | $- | $- |
| Net Change in Cash | $- | $- | $- |
| Cash at End of Period | $1.14K | $534 | $606 |
| Cash at Beginning of Period | $534 | $606 | $3.12K |
| Operating Cash Flow | $-6.69M | $-1.75M | $6.51M |
| Capital Expenditure | $-3 | $-4 | $1 |
| Free Cash Flow | $-6.69M | $-1.75M | $6.51M |
BlackRock Health Sciences Trust Dividends
Explore BlackRock Health Sciences Trust's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.00x
BlackRock Health Sciences Trust Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.2621 | $0.2621 | March 14, 2025 | March 14, 2025 | March 31, 2025 | March 03, 2025 |
| $0.2621 | $0.2621 | February 14, 2025 | February 14, 2025 | February 28, 2025 | February 03, 2025 |
| $0.2621 | $0.2621 | January 15, 2025 | January 15, 2025 | January 31, 2025 | January 02, 2025 |
| $0.2621 | $0.2621 | December 16, 2024 | December 16, 2024 | December 23, 2024 | November 22, 2024 |
| $0.213 | $0.213 | November 15, 2024 | November 15, 2024 | November 29, 2024 | November 01, 2024 |
| $0.213 | $0.213 | October 15, 2024 | October 15, 2024 | October 31, 2024 | September 12, 2024 |
| $0.213 | $0.213 | September 16, 2024 | September 16, 2024 | September 30, 2024 | September 03, 2024 |
| $0.213 | $0.213 | August 15, 2024 | August 15, 2024 | August 30, 2024 | August 01, 2024 |
| $0.213 | $0.213 | July 15, 2024 | July 15, 2024 | July 31, 2024 | July 01, 2024 |
| $0.213 | $0.213 | June 14, 2024 | June 14, 2024 | June 28, 2024 | June 03, 2024 |
| $0.213 | $0.213 | May 14, 2024 | May 15, 2024 | May 31, 2024 | |
| $0.213 | $0.213 | April 12, 2024 | April 15, 2024 | April 30, 2024 | April 01, 2024 |
| $0.213 | $0.213 | March 14, 2024 | March 15, 2024 | March 28, 2024 | March 01, 2024 |
| $0.213 | $0.213 | February 14, 2024 | February 15, 2024 | February 29, 2024 | February 01, 2024 |
| $0.213 | $0.213 | January 11, 2024 | January 12, 2024 | January 31, 2024 | January 02, 2024 |
| $0.213 | $0.213 | December 14, 2023 | December 15, 2023 | December 20, 2023 | December 05, 2023 |
| $0.213 | $0.213 | November 14, 2023 | November 15, 2023 | November 30, 2023 | November 01, 2023 |
| $0.213 | $0.213 | October 13, 2023 | October 16, 2023 | October 31, 2023 | October 02, 2023 |
| $0.213 | $0.213 | September 14, 2023 | September 15, 2023 | September 29, 2023 | September 01, 2023 |
| $0.213 | $0.213 | August 14, 2023 | August 15, 2023 | August 31, 2023 | August 01, 2023 |
BlackRock Health Sciences Trust News
Read the latest news about BlackRock Health Sciences Trust, including recent articles, headlines, and updates.
B&M derating overdone, says leading US investment bank
Citi has reiterated its bullish stance on B&M European Value Retail SA (LSE:BME), arguing the recent slide in the discount retailer's share price is overdone and fails to reflect the company's earnings potential. Despite a 7% cut to earnings forecasts so far this year and a cautious mood among investors, Citi said B&M remains a dominant player in UK variety discount retail, with 35% of market revenue and over half of the profit share.
2 Defensive Closed-End Funds Delivering Monthly Distributions
The broader equity market has become more volatile, with mega-cap tech declines affecting the S&P 500 and Nasdaq flirting with correction territory. We are looking at two funds that provide relatively more defensive positioning that can help dampen some of the overall volatility while also paying healthy monthly distributions. However, it is important to remember that these funds aren't completely immune to volatility themselves, and with discounts/premiums in CEFs, that's also another consideration.
Should You Invest $100,000 In Today's Market?
The market is experiencing a correction, with a potential bear market looming, making gradual investment over 3-6 months advisable for long-term investors. Understanding personal risk tolerance is crucial before investing, as it dictates how one handles market downturns and portfolio drawdowns. The article presents three different investment strategies. We are going to discuss how strategically you can deploy your capital on a gradual basis.
4 Closed-End Fund Buys (And A Sell) In The Month Of February 2025
The tech-heavy Nasdaq started to dip toward the end of February, but a strong last trading day of the month rally clawed back some of those losses. The equal-weighted S&P 500, as measured by the Invesco ETF RSP, held up reasonably well thanks to the value sectors putting up some better performance. Every month, I put some cash to work to grow my CEF portfolio income, though I've been allowing my cash pile to also grow over the last year or so.
BME: Questionable Distribution Coverage (Rating Downgrade)
BlackRock Health Sciences Trust has seen a 5% price decline over the past year, with a total return of 1.5% including distributions. BME's high 7.8% dividend yield is attractive but potentially unsustainable due to reliance on net realized gains and weak net investment income. The fund's option writing strategy caps price upside, contributing to underperformance compared to peer healthcare funds and traditional ETFs like XLV.
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE: BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE: BUI), Bla.
B&M: Heavyweight cuts valuation after earnings alter; stays underweight
The remnants of bank and broker reaction to B&M European Value Retail SA's (LSE:BME) profit warning earlier this week continue to trickle out. On Thursday it was the turn of JP Morgan, which cut its price target to 299p from 320p.
B&M's lack of UK growth improvement disappointing, but some analysts say 'buy'
B&M European Value Retail SA (LSE:BME) festive trading update was much weaker than expected, Deutsche Bank said, but the past quarter could represent the "trough" before a potential rebound. Group sales growth of 2.6% for the third quarter was around a 4% miss versus the consensus forecast, the bank noted.
B&M hands out £150m special dividend after 'disciplined' Christmas
B&M European Value Retail SA (LSE:BME) has announced a special dividend worth £151 million as it reported good sales of seasonal products over Christmas. The value chain said like-for-like sales in its UK arm dropped by 2.8% in the 13 weeks to 28 December 2024 but had been positive in the last few weeks, a trend that has continued into this year.
BME And FLC: There Are Still Pockets Of Opportunities
Closed-end funds have seen significant discount narrowing in 2024 across the board, as discounts have been cut in more than half on average. Despite record highs being hit regularly this year in the S&P 500, NASDAQ 100, and DJIA, opportunities still exist as not everything has been participating on the upside equally. Investors could consider funds like the BME and FLC, which may still offer attractive entry points despite the overall discount narrowing in the CEF space and elevated broader equity markets.
11 Closed-End Fund Buys In The Month Of November 2024
This month, I've added to 11 different positions, but most of these were related to repurchases after the BlackRock tender offers. While I added to 11 different positions, these were all positions I had already held previously, so there were no new positions this month. In fact, I sold out of a fund to consolidate my holdings and reduce the number of funds held, as I did last month as well.
B&M jumps as spending pressures help drive discounter's sales
B&M European Value Retail SA (LSE:BME) shares gained ground on Thursday after the discounter posted improved first-half figures as cost pressures continued to drive demand. Group sales climbed by 3.7% to £2.64 billion over the six months to September, aided by a 6.0% uptick across the UK in the second quarter, B&M reported on Thursday.
BME: Defensive Healthcare Exposure With A Tender Offer Opportunity
BlackRock Health Sciences Trust offers exposure to healthcare companies and employs a covered call strategy to generate option premiums to help support the distribution. The latest tender offer measurement period for BlackRock discount management programs has come to a close, and BME made the list, but it was close this time. The fund's 6.15% distribution yield might not be the most exciting, but it is one of the most consistent and steady you'll find in the CEF space.
BME: Discount To NAV But High Fees And Volatility
BME has delivered solid long-term returns since its 2005 launch, earning positive ratings from Seeking Alpha analysts, with most recent articles rating it a Buy or Strong Buy. The trust has a relatively high expense ratio and has experienced significant volatility related to trading levels relative to NAV. BlackRock recently announced a tender offer that will allow 2.5% of the fund's units to be repurchased at 98% of NAV.
9 Closed-End Fund Buys In The Month Of August 2024
The broader equity market saw declines in early August but ended near all-time highs to finish off the month. I put some capital to work this month at the low, but not as much as I had planned initially, as the market swiftly recovered. Most of the moves this month were corporate action-driven events, primarily the BlackRock tender offers, as we finished up the first measurement period.
Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers: BMEZ, BME, BGY
NEW YORK--(BUSINESS WIRE)---- $BGY--The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund's tender offer (each, a “Tender Offer”) for up to 2.5% of its outstanding common shares (the “Shares”). Each Tender Offer commenced on July 18, 2024 and expired at 5:00 p.m. Eastern time on August 19, 2024. Based on preliminary information, the number of Shares properly tendered for each Fund and not withdrawn is noted in the table below. Fund.
BME: An Attractive Discount On This Healthcare CEF
BlackRock Health Sciences Trust (BME) offers exposure to the healthcare space while also utilizing a covered call strategy. BME's discount has narrowed since our last update but remains attractive, with the potential for attractive returns going forward. BME's distribution yield may be more modest than other CEFs, but that has helped it boast of never having to cut the regular distribution and helped it provide some capital.
BME: Future Interest Rate Cuts May Be A Catalyst
BlackRock Health Sciences Trust trades at an attractive discount to net asset value. The dividend yield of 6.1% remains supported from net investment income. Some weakness revolves around the use of return of capital, however. Future interest rate cuts may serve as a price catalyst. Inflation continues to cool while the unemployment rate ticks upward.
B&M launches store openings as sales edge higher
B&M European Value Retail SA (LSE:BME), the discount retailer, saw its sales edge higher in the first quarter helped by new store openings and volume growth. Group sales increased by 2.4%, reaching £1,345 million for the 13-week period ending 29 June 2024.
BME: Quality Healthcare Fund With 6% Income And An Attractive Discount
BlackRock Health Sciences Trust is a healthcare sector-specific closed-end fund that invests in a fairly diversified portfolio of common stocks in the healthcare sector. It currently provides a reasonable yield of 6.3% plus an attractive discount of close to -8% (below NAV). The BME closed-end fund has a very decent long-term record of nearly 19 years, matching and even exceeding the performance of the S&P 500. However, the recent near and midterm performance has been lackluster.
5 Best CEFs This Month For A 9% Yield (June 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
B&M shares tumble on ‘curious' omission of guidance in results
B&M European Value Retail SA (LSE:BME) shares have tumbled more than 6% after it posted what analysts said was a “curious” set of full-year results. During the twelve months, underlying earnings came in at the top end of guidance, on the back of new store openings and what management said was volume-led growth.
B&M sees new store openings drive profit surge
B&M European Value Retail SA (LSE:BME), the discount retailer, saw its profits hit the top end of guidance for the year as it expanded its store footprint and demand spiked. Full-year underlying earnings reached £629 million, compared to guidance of between £620 million and £630 million, marking a 9.7% jump year-on-year.
Similar Companies
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
Price: $21.08
Market Cap: $723.91M
Blackrock Resources & Commodities Strategy Trust
BCX
Price: $9.34
Market Cap: $749.05M
BlackRock Enhanced Capital and Income Fund, Inc.
CII
Price: $18.49
Market Cap: $775.97M
Duff & Phelps Utility and Infrastructure Fund Inc.
DPG
Price: $12.14
Market Cap: $450.76M
Eaton Vance Tax-Managed Buy-Write Opportunities Fund
ETV
Price: $13.29
Market Cap: $1.55B
Eaton Vance Tax-Managed Global Diversified Equity Income Fund
EXG
Price: $8.16
Market Cap: $2.50B
Columbia Seligman Premium Technology Growth Fund
STK
Price: $28.30
Market Cap: $468.44M
Related Metrics
Explore detailed financial metrics and analysis for BME.